Influence of perfusion on high-intensity focused ultrasound prostate ablation: A first-pass MRI study

Magnetic Resonance in Medicine

Volumn 58, Issue 1, 2007, Pages 119-127

  Wiart, Marlène ^a,b,c   Curiel, Laura ^a,d   Gelet, Albert ^a,d,e   Lyonnet, Denis ^a,d,e,f   Chapelon, Jean Yves ^a,d   Rouvière, Olivier ^a,d,e,f  

^a UNIVERSITÉ DE LYON   (France)

^b UNIVERSITÉ DE LYON   (France)

^c UNIVERSITÉ DE LYON   (France)

^d INSERM   (France)

^e EDOUARD HERRIOT HOSPITAL   (France)

^f UNIVERSITÉ LYON 1   (France)

Author keywords

Blood flow; Contrast agent; HIFU therapy; Perfusion; Prostate neoplasm

Indexed keywords

ANTIGENS; BLOOD; DISEASES; HEMODYNAMICS; MAGNETIC RESONANCE IMAGING; PATIENT TREATMENT; ULTRASONICS;

BLOOD FLOW; CONTRAST AGENT; HIFU THERAPY; PERFUSION; PROSTATE NEOPLASMS;

UROLOGY;

PROSTATE SPECIFIC ANTIGEN; TRACER;

ADULT; AGED; ARTICLE; BLOOD FLOW; CANCER PATIENT; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PERFUSION; PROSTATE CANCER; QUANTITATIVE ANALYSIS; RADIOFREQUENCY ABLATION; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; VALIDATION PROCESS;

EID: 34547726347     PISSN: 07403194     EISSN: 15222594     Source Type: Journal    
DOI: 10.1002/mrm.21271     Document Type: Article

References (49)

1. Poissonnier L, Chapelon JY, Rouviere O, Curiel L, Bouvier R, Martin X, Dubernard JM, Gelet A. Control of prostate cancer by transrectal HIFU in 227 patients. Eur Urol 2007;51:381-387.
2. Watkin NA, ter Haar GR, Rivens I. The intensity dependence of the site of maximal energy deposition in focused ultrasound surgery. Ultrasound Med Biol 1996;22:483-491.
3. Uchida T, Ohkusa H, Yamashita H, Shoji S, Nagata Y, Hyodo T, Satoh T. Five years experience of transrectal high-intensity focused ultrasound using the Sonablate device in the treatment of localized prostate cancer. Int J Urol 2006;13:228-233.
4. Beerlage HP, Thuroff S, Debruyne FM, Chaussy C, de la Rosette JJ. Transrectal high-intensity focused ultrasound using the Ablatherm device in the treatment of localized prostate carcinoma. Urology 1999;54:273-277.
5. Sibille A, Prat F, Chapelon JY, Abou el Fadil F, Henry L, Theillere Y, Ponchon T, Cathignol D. Extracorporeal ablation of liver tissue by high-intensity focused ultrasound. Oncology 1993;50:375-379.
6. Chen L, ter Haar G, Hill CR. Influence of ablated tissue on the formation of high-intensity focused ultrasound lesions. Ultrasound Med Biol 1997;23:921-931.
7. Chen L, ter Haar G, Hill CR, Dworkin M, Carnochan P, Young H, Bensted JP. Effect of blood perfusion on the ablation of liver parenchyma with high-intensity focused ultrasound. Phys Med Biol 1993;38:1661-1673.
8. Lyons BE, Samulski TV, Cox RS, Fessenden P. Heat loss and blood flow during hyperthermia in normal canine brain. I: Empirical study and analysis. Int J Hyperthermia 1989;5:225-247.
9. Tilly W, Wust P, Rau B, Harder C, Gellermann J, Schlag P, Budach V, Felix R. Temperature data and specific absorption rates in pelvic tumours: predictive factors and correlations. Int J Hyperthermia 2001;17:172-188.
10. Bolmsjo M, Sturesson C, Wagrell L, Andersson-Engels S, Mattiasson A. Optimizing transurethral microwave thermotherapy: a model for studying power, blood flow, temperature variations and tissue destruction. Br J Urol 1998;81:811-816.
11. Larson TR, Collins JM. An accurate technique for detailed prostatic interstitial temperature-mapping in patients receiving microwave thermal treatment. J Endourol 1995;9:339-347.
12. Xu LX, Zhu L, Holmes KR. Thermoregulation in the canine prostate during transurethral microwave hyperthermia, Part II: Blood flow response. Int J Hyperthermia 1998;14:65-73.
13. Xu LX, Zhu L, Holmes KR. Thermoregulation in the canine prostate during transurethral microwave hyperthermia, Part I: Temperature response. Int J Hyperthermia 1998;14:29-37.
14. Billard BE, Hynynen K, Roemer RB. Effects of physical parameters on high temperature ultrasound hyperthermia. Ultrasound Med Biol 1990;16:409-420.
15. Rouviere O, Curiel L, Chapelon JY, Bouvier R, Ecochard R, Gelet A, Lyonnet D. Can color Doppler predict the uniformity of HIFU-induced prostate tissue destruction? Prostate 2004;60:289-297.
16. Uchida T, Illing RO, Cathcart PJ, Emberton M. To what extent does the prostate-specific antigen nadir predict subsequent treatment failure after transrectal high-intensity focused ultrasound therapy for presumed localized adenocarcinoma of the prostate? BJU Int 2006;98:537-539.
17. Padhani AR. MRI for assessing antivascular cancer treatments. Br J Radiol 2003;76(Spec No 1):S60-80.
18. Futterer JJ, Engelbrecht MR, Huisman HJ, Jager GJ, Hulsbergen-van De Kaa CA, Witjes JA, Barentsz JO. Staging prostate cancer with dynamic contrast-enhanced endorectal MR imaging prior to radical prostatectomy: experienced versus less experienced readers. Radiology 2005;237:541-549.
19. Hara N, Okuizumi M, Koike H, Kawaguchi M, Bilim V. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is a useful modality for the precise detection and staging of early prostate cancer. Prostate 2005;62:140-147.
20. Buckley DL, Roberts C, Parker GJ, Logue JP, Hutchinson CE. Prostate cancer: evaluation of vascular characteristics with dynamic contrast-enhanced T1-weighted MR imaging - initial experience. Radiology 2004;233:709-715.
21. Girouin N, Mege-Lechevallier F, Tonina Senes A, Bissery A, Rabilloud M, Marechal JM, Colombel M, Lyonnet D, Rouviere O. Prostate dynamic contrast-enhanced MRI with simple visual diagnostic criteria: is it reasonable? Eur Radiol 2007;17(6):1498-1509.
22. Gelet A, Chapelon JY, Bouvier R, Rouviere O, Lasne Y, Lyonnet D, Dubernard JM. Transrectal high-intensity focused ultrasound: minimally invasive therapy of localized prostate cancer. J Endourol 2000;14:519-528.
23. Gelet A, Chapelon JY, Bouvier R, Rouviere O, Lyonnet D, Dubernard JM. Transrectal high intensity focused ultrasound for the treatment of localized prostate cancer: factors influencing the outcome. Eur Urol 2001;40:124-129.
24. Miles KA. Measurement of tissue perfusion by dynamic computed tomography. Br J Radiol 1991;64:409-412.
25. Padhani AR, Gapinski CJ, Macvicar DA, Parker GJ, Suckling J, Revell PB, Leach MO, Dearnaley DP, Husband JE. Dynamic contrast enhanced MRI of prostate cancer: correlation with morphology and tumour stage, histological grade and PSA. Clin Radiol 2000;55:99-109.
26. Jerosch-Herold M, Seethamraju RT, Swingen CM, Wilke NM, Stillman AE. Analysis of myocardial perfusion MRI. J Magn Reson Imaging 2004;19:758-770.
27. Willats L, Connelly A, Calamante F. Improved deconvolution of perfusion MRI data in the presence of bolus delay and dispersion. Magn Reson Med 2006;56:146-156.
28. Livingston EH. Who was Student and why do we care so much about his t-test? J Surg Res 2004;118:58-65.
29. Sipola P, Lauerma K, Husso-Saastamoinen M, Kuikka JT, Vanninen E, Laitinen T, Manninen H, Niemi P, Peuhkurinen K, Jaaskelainen P, Laakso M, Kuusisto J, Aronen HJ. First-pass MR imaging in the assessment of perfusion impairment in patients with hypertrophic cardiomyopathy and the Asp175Asn mutation of the alpha-tropomyosin gene. Radiology 2003;226:129-137.
30. Padhani AR, MacVicar AD, Gapinski CJ, Dearnaley DP, Parker GJ, Suckling J, Leach MO, Husband JE. Effects of androgen deprivation on prostatic morphology and vascular permeability evaluated with MR imaging. Radiology 2001;218:365-374.
31. Ostergaard L, Weisskoff RM, Chesler DA, Gyldensted C, Rosen BR. High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part I: Mathematical approach and statistical analysis. Magn Reson Med 1996;36:715-725.
32. Christian TF, Rettmann DW, Aletras AH, Liao SL, Taylor JL, Balaban RS, Arai AE. Absolute myocardial perfusion in canines measured by using dual-bolus first-pass MR imaging. Radiology 2004;232:677-684.
33. Inaba T. Quantitative measurements of prostatic blood flow and blood volume by positron emission tomography. J Urol 1992;148:1457-1460.
34. Noworolski SM, Henry RG, Vigneron DB, Kurhanewicz J. Dynamic contrast-enhanced MRI in normal and abnormal prostate tissues as defined by biopsy, MRI, and 3D MRSI. Magn Reson Med 2005;53:249-255.
35. Uchida T, Illing RO, Cathcart PJ, Emberton M. The effect of neoadjuvant androgen suppression on prostate cancer-related outcomes after high-intensity focused ultrasound therapy. BJU Int 2006;98:770-772.
36. Shabsigh A, Chang DT, Heitjan DF, Kiss A, Olsson CA, Puchner PJ, Buttyan R. Rapid reduction in blood flow to the rat ventral prostate gland after castration: preliminary evidence that androgens influence prostate size by regulating blood flow to the prostate gland and prostatic endothelial cell survival. Prostate 1998;36:201-206.
37. Husband JE, Padhani AR, MacVicar AD, Revell P. Magnetic resonance imaging of prostate cancer: comparison of image quality using endorectal and pelvic phased array coils. Clin Radiol 1998;53:673-681.
38. Hindley J, Gedroyc WM, Regan L, Stewart E, Tempany C, Hynyen K, McDannold N, Inbar Y, Itzchak Y, Rabinovici J, Kim HS, Geschwind JF, Hesley G, Gostout B, Ehrenstein T, Hengst S, Sklair-Levy M, Shushan A, Jolesz F. MRI guidance of focused ultrasound therapy of uterine fibroids: early results. AJR Am J Roentgenol 2004;183:1713-1719.
39. Van den Berg CA, Van de Kamer JB, De Leeuw AA, Jeukens CR, Raaymakers BW, van Vulpen M, Lagendijk JJ. Towards patient specific thermal modelling of the prostate. Phys Med Biol 2006;51:809-825.
40. Harvey CJ, Blomley MJ, Dawson P, Morgan JA, Dooher A, Deponte J, Vernon CC, Price P. Functional CT imaging of the acute hyperemic response to radiation therapy of the prostate gland: early experience. J Comput Assist Tomogr 2001;25:43-49.
41. van Vulpen M, Raaymakers BW, de Leeuw AA, van de Kamer JB, van Moorselaar RJ, Hobbelink MG, Battermann JJ, Lagendijk JJ. Prostate perfusion in patients with locally advanced prostate carcinoma treated with different hyperthermia techniques. J Urol 2002;168(Pt 1):1597-1602.
42. Henderson E, Milosevic MF, Haider MA, Yeung IW. Functional CT imaging of prostate cancer. Phys Med Biol 2003;48:3085-3100.
43. Jeukens CR, van den Berg CA, Donker R, van Vulpen M, Bakker CJ, van Leeuwen MS, van der Heide UA. Feasibility and measurement precision of 3D quantitative blood flow mapping of the prostate using dynamic contrast-enhanced multi-slice CT. Phys Med Biol 2006;51:4329-4343.
44. Paternostro G, Camici PG, Lammerstma AA, Marinho N, Baliga RR, Kooner JS, Radda GK, Ferrannini E. Cardiac and skeletal muscle insulin resistance in patients with coronary heart disease. A study with positron emission tomography. J Clin Invest 1996;98:2094-2099.
45. Ruotsalainen U, Raitakari M, Nuutila P, Oikonen V, Sipila H, Teras M, Knuuti MJ, Bloomfield PM, Iida H. Quantitative blood flow measurement of skeletal muscle using oxygen-15-water and PET. J Nucl Med 1997;38:314-319.
46. Burchert W, Schellong S, van den Hoff J, Meyer GJ, Alexander K, Hundeshagen H. Oxygen-15-water PET assessment of muscular blood flow in peripheral vascular disease. J Nucl Med 1997;38:93-98.
47. Bonadonna RC, Saccomani MP, Del Prato S, Bonora E, DeFronzo RA, Cobelli C. Role of tissue-specific blood flow and tissue recruitment in insulin-mediated glucose uptake of human skeletal muscle. Circulation 1998;98:234-241.
48. Boushel R, Langberg H, Green S, Skovgaard D, Bulow J, Kjaer M. Blood flow and oxygenation in peritendinous tissue and calf muscle during dynamic exercise in humans. J Physiol 2000;524(Pt 1):305-313.
49. Lin CC, Ding HJ, Yen RF, Wang JJ, Ho ST, Kao A. High prevalence of asymptomatically poor muscle perfusion of lower extremities measured in type II diabetes patients with abnormal myocardial perfusion. J Diabetes Complications 2003;17:365-368.